corneal dystrophic epidermolysis bullosa | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

3,309 results for “corneal dystrophic epidermolysis bullosa”

Trials

View all 2673 →

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

16 participants · First posted Jun 12, 2025

MSC EVs in Dystrophic Epidermolysis Bullosa

8 participants · First posted Nov 22, 2019

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

40 participants · First posted Aug 20, 2024

Drugs

View all 136 →

Epidermolysis Bullosa(Healiva)

Epidermolysis Bullosa(CorrGene Biotechnology)

recombinant human type VII pro-collagen (dystrophic epidermolysis bullosa)

Organizations

View all 29 →

Abeona Therapeutics

United States

CORNEAL CONSULTANTS OF INDIANA, P.C.

United States

Glaukos Corporation

United States

News

View all 471 →

Krystal Biotech Initiates Phase 3 Trial of KB803 Gene Therapy for Corneal Complications in Dystrophic Epidermolysis Bullosa

Key Phase 3 Trials from Moderna, Sarepta, and Krystal Biotech Set to Drive 2026 Biotech Performance

FDA Approves Groundbreaking Gene Therapy for Dystrophic Epidermolysis Bullosa

Page 1 of 331